Microvascular Modifications in Diabetic Retinopathy

被引:167
作者
Durham, Jennifer T. [1 ,2 ]
Herman, Ira M. [1 ,2 ]
机构
[1] Tufts Univ, Sackler Sch Grad Biomed Sci, Program Cellular & Mol Physiol, Dept Mol Physiol & Pharmacol, Boston, MA 02111 USA
[2] Tufts Univ, Ctr Innovat Wound Healing Res, Boston, MA 02111 USA
关键词
Angiogenesis; Endothelial cell; Pericyte; Cytoskeleton; VEGF; Adenovirus/AAV; PEDF; PPE1; Microvascular modifications; Diabetic retinopathy; ENDOTHELIAL GROWTH-FACTOR; EPITHELIUM-DERIVED FACTOR; INTRAVITREAL BEVACIZUMAB AVASTIN; VASCULAR-PERMEABILITY FACTOR; MEDIATED GENE-TRANSFER; SINGLE-CHAIN DIABODY; PROTEIN-KINASE-C; RETINAL NEOVASCULARIZATION; CHOROIDAL NEOVASCULARIZATION; TUMOR-CELLS;
D O I
10.1007/s11892-011-0204-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Patients struggling with diabetes are at elevated risks for several sight-threatening diseases, including proliferative diabetic retinopathy (DR). DR manifests in two stages: first, the retinal microvasculature is compromised and capillary degeneration occurs; subsequently, an over-compensatory angiogenic response is initiated. Early changes in the retinal microcirculation include disruptions in blood flow, thickening of basement membrane, eventual loss of mural cells, and the genesis of acellular capillaries. Endothelial apoptosis and capillary dropout lead to a hypoxic inner retina, alterations in growth factors, and upregulation of inflammatory mediators. With disease progression, pathologic angiogenesis generates abnormal preretinal microvessels. Current therapies, which include panretinal photocoagulation and vitrectomy, have remained unaltered for several decades. With several exciting preclinical advances, emergent technologies and innovative cellular targets may offer newfound hope for developing "next-generation" interventional or preventive clinical approaches that will significantly advance current standards of care and clinical outcomes.
引用
收藏
页码:253 / 264
页数:12
相关论文
共 160 条
  • [101] Li WY, 1997, CHINESE MED J-PEKING, V110, P659
  • [102] Luna J, 1996, LAB INVEST, V75, P563
  • [103] A comparative study on the anti-angiogenic effects of DNA-damaging and cytoskeletal-disrupting agents
    Mabeta, Peace
    Pepper, Michael S.
    [J]. ANGIOGENESIS, 2009, 12 (01) : 81 - 90
  • [104] VEGF-A165b Is Cytoprotective and Antiangiogenic in the Retina
    Magnussen, Anette L.
    Rennel, Emma S.
    Hua, Jing
    Bevan, Heather S.
    Beazley Long, Nicholas
    Lehrling, Christina
    Gammons, Melissa
    Floege, Juergen
    Harper, Steven J.
    Agostini, Hansjuergen T.
    Bates, David O.
    Churchill, Amanda J.
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2010, 51 (08) : 4273 - 4281
  • [105] Role of RhoA, mDia, and ROCK in cell shape-dependent control of the Skp2-p27kip1 pathway and the G1/S transition
    Mammoto, A
    Huang, S
    Moore, K
    Oh, P
    Ingber, DE
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (25) : 26323 - 26330
  • [106] A mechanosensitive transcriptional mechanism that controls angiogenesis
    Mammoto, Akiko
    Connor, Kip M.
    Mammoto, Tadanori
    Yung, Chong Wing
    Huh, Dongeun
    Aderman, Christopher M.
    Mostoslavsky, Gustavo
    Smith, Lois E. H.
    Ingber, Donald E.
    [J]. NATURE, 2009, 457 (7233) : 1103 - U57
  • [107] In vivo efficacy of HSV-TK transcriptionally targeted to the tumour vasculature is augmented by combination with cytotoxic chemotherapy
    Mavria, G
    Harrington, KJ
    Marshall, CJ
    Porter, CD
    [J]. JOURNAL OF GENE MEDICINE, 2005, 7 (03) : 263 - 275
  • [108] MCLEOD DS, 1995, AM J PATHOL, V147, P642
  • [109] Rapid and persistent regression of severe new vessels on the disc in proliferative diabetic retinopathy after a single intravitreal injection of pegaptanib
    Mendrinos, Efstratios
    Donati, Guy
    Pournaras, Constantin J.
    [J]. ACTA OPHTHALMOLOGICA, 2009, 87 (06) : 683 - 684
  • [110] MILLER JW, 1994, AM J PATHOL, V145, P574